Pharma industry is facing a new era. Once a new drug is released to the market, drug manufacturers need to know how their products behave in a real life environment. After usually more than ten years of drug development and clinical tests, health insurances and others who pay for a drug demand proof of efficiacy, information on long term consequences and interferences with other medicine. Therefore, a big amount of "real life evidence data" is gathered by leading pharma companies like Bayer. In a more and more digital world, problems and opportunities for this process emerge. That is why Bayer Healthcare has challenged a team of 2 Finnish and 4 German students with the task to improve gathering, managing and merging real life evidence data. Soon after exploring the problem space, the students found that data structure and quality varies heavily among different sources, institutions and countries. Thus, instead of trying to merge existing sources, they propose to create a crowd-powered open and combined data source by leveraging the increasing potential of health awareness and self-tracking. With LINK, the team built a platform for everyone to improve healthcare research by participating in studies posed by researchers. LINK makes it easy for people to contribute data through interactive questionaires, provided blood values and integrated self-tracking devices. Using an app for mobile devices, study participants can track their medicine intake, gather data and share among healthcare research. With study incentives and a real patient story, researchers are able to reach out to the right participants for their studies.
LINK is a step towards a real life evidence process, where patients and pharma work closely together to create the medicine of the future.